Stock Track | Krystal Biotech Soars 5.25% Intraday on Strong Q1 Earnings Beat and FDA RMAT Designation

Stock Track

May 04

Krystal Biotech Inc.'s stock experienced a significant surge of 5.25% during Monday's intraday trading session.

The sharp upward movement follows the company's release of robust first-quarter 2026 financial results. Krystal Biotech reported quarterly adjusted earnings of $1.83 per share, which exceeded the mean analyst estimate of $1.42 per share and represented a substantial increase from $1.20 per share in the same quarter last year. Revenue for the quarter rose 31.9% year-over-year to $116.36 million, driven primarily by the growth of its VYJUVEK product.

Additionally, investor sentiment received a boost from regulatory news. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the company's redosable HSV-based immunotherapy candidate for advanced or metastatic non-small cell lung cancer. This designation facilitates more frequent interactions with the FDA and potential pathways for accelerated development and review.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1114814253"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1114814253\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1114814253?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-04 22:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1114814253","market":"sg","top_or_hot":-1,"title":"Stock Track | Krystal Biotech Soars 5.25% Intraday on Strong Q1 Earnings Beat and FDA RMAT Designation","media":"Stock Track","content":"<p>Krystal Biotech Inc.'s stock experienced a significant surge of 5.25% during Monday's intraday trading session.</p><p>The sharp upward movement follows the company's release of robust first-quarter 2026 financial results. Krystal Biotech reported quarterly adjusted earnings of $1.83 per share, which exceeded the mean analyst estimate of $1.42 per share and represented a substantial increase from $1.20 per share in the same quarter last year. Revenue for the quarter rose 31.9% year-over-year to $116.36 million, driven primarily by the growth of its VYJUVEK product.</p><p>Additionally, investor sentiment received a boost from regulatory news. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the company's redosable HSV-based immunotherapy candidate for advanced or metastatic non-small cell lung cancer. This designation facilitates more frequent interactions with the FDA and potential pathways for accelerated development and review.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Krystal Biotech Soars 5.25% Intraday on Strong Q1 Earnings Beat and FDA RMAT Designation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Krystal Biotech Soars 5.25% Intraday on Strong Q1 Earnings Beat and FDA RMAT Designation\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-05-04 22:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Krystal Biotech Inc.'s stock experienced a significant surge of 5.25% during Monday's intraday trading session.</p><p>The sharp upward movement follows the company's release of robust first-quarter 2026 financial results. Krystal Biotech reported quarterly adjusted earnings of $1.83 per share, which exceeded the mean analyst estimate of $1.42 per share and represented a substantial increase from $1.20 per share in the same quarter last year. Revenue for the quarter rose 31.9% year-over-year to $116.36 million, driven primarily by the growth of its VYJUVEK product.</p><p>Additionally, investor sentiment received a boost from regulatory news. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the company's redosable HSV-based immunotherapy candidate for advanced or metastatic non-small cell lung cancer. This designation facilitates more frequent interactions with the FDA and potential pathways for accelerated development and review.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KRYS","symbol_name":"Krystal Biotech Inc.","start_time":0,"source_url":"","article_id":"1114814253","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1114814253","pubTimestamp":1777903424,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Krystal Biotech Inc.'s stock experienced a significant surge of 5.25% during Monday's intraday trading session.The sharp upward movement follows the company's release of robust first-quarter 2026...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KRYS":"Krystal Biotech Inc."},"translate_title":"个股追踪|Krystal Biotech盘中大涨5.25%，因Q1盈利强劲且获得FDA RMAT指定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRYS":1},"content_text":"Krystal Biotech Inc.'s stock experienced a significant surge of 5.25% during Monday's intraday trading session.The sharp upward movement follows the company's release of robust first-quarter 2026 financial results. Krystal Biotech reported quarterly adjusted earnings of $1.83 per share, which exceeded the mean analyst estimate of $1.42 per share and represented a substantial increase from $1.20 per share in the same quarter last year. Revenue for the quarter rose 31.9% year-over-year to $116.36 million, driven primarily by the growth of its VYJUVEK product.Additionally, investor sentiment received a boost from regulatory news. The U.S. Food and Drug Administration granted Regenerative Medicine Advanced Therapy (RMAT) designation to KB707, the company's redosable HSV-based immunotherapy candidate for advanced or metastatic non-small cell lung cancer. This designation facilitates more frequent interactions with the FDA and potential pathways for accelerated development and review.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}